By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MDPeter's takeaways on liver health, heart rate variability, AI in medicine & more (PS 2 sneak peek)
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
CHAPTERS
- 0:02 – 2:41
Welcome and the quarterly summary format
The host welcomes Peter to the second quarterly podcast summary and lists the topics ahead. Peter reflects on the strong response to the first summary episode in June and how people used it.
- •Second quarterly summary, following the first released in June
- •Planned topics include liver health, heart rate variability, AI in medicine, klotho and Alzheimer's, and lactate
- •Listeners said they used it to catch up, to decide which episodes to hear, or to refresh their memory
- •Peter says it may have drawn the most emails of any single podcast
- •The summaries are meant as refreshers, not replacements for the full episodes
- 2:41 – 5:21
Why the liver matters and how alcohol harms it
Peter begins the Julia Wattacheril episode recap by explaining that the liver has no extracorporeal support and performs three broad functions. He then covers how alcohol damages the liver and how much ethanol is in a standard drink.
- •Kidneys, lungs and heart can be supported outside the body, but liver failure leaves transplant as the only option
- •Liver functions fall into metabolism, protein synthesis and detoxification
- •Acetaldehyde overwhelms the redox potential of liver cells, drawing free radicals and inflammatory cells
- •A standard drink has about 14-15 grams of ethanol, and home pours are often larger than five ounces of wine
- 5:21 – 7:30
From NAFLD to MASLD: definition and diagnostic criteria
Peter explains the shift in terminology from NAFLD to MASLD and what the diagnosis requires. He notes the near-total overlap between the two and the link to insulin resistance.
- •NAFLD is the fastest growing liver disease in the developed world and may become the leading reason for liver transplant within a decade
- •MASLD is tied to insulin resistance, metabolic syndrome and type 2 diabetes
- •Per Julia, 99.6 percent of people meeting NAFLD criteria also meet MASLD criteria
- •Diagnosis requires metabolic dysfunction and at least five percent of hepatocytes containing fat, but not fibrosis
- 7:30 – 10:15
Kids versus adults: fibrosis patterns and delayed enzyme rises
Peter describes how fibrosis patterns differ between children and adults, centered on the portal and central veins. This affects when liver enzymes rise, so waiting for elevated transaminases may detect disease late.
- •In kids, fibrosis centers around the portal vein, so ALT, AST and GGT rise earlier
- •In adults, steatosis and fibrosis occur nearer the central vein, delaying enzyme elevation
- •Transaminase elevation as a threshold for concern may wait too long
- •Top three causes of liver injury: MASLD, alcoholic liver disease, and infections such as hepatitis
- 10:15 – 12:56
Peter's story of an unrecognized fatty liver
In response to a question about how MASLD became the leading cause, Peter recounts operating on a patient who denied drinking but had a fatty liver. He says NAFLD was not widely recognized twenty-plus years ago but was seen as an epidemic by about 2010-2012.
- •Pre-op assessment includes alcohol intake because withdrawal after surgery can be fatal
- •The patient denied drinking, yet his liver looked fatty in surgery
- •Peter now believes the patient had what would be called NAFLD
- •By 2010-2012 most people viewed it as an epidemic that would burden liver transplantation
- 12:56 – 15:26
Hepatitis B and C and liver cancer risk
Peter covers hep B and hep C, including vaccine and treatment availability, and why they matter for liver failure and hepatocellular carcinoma. He also describes how cancer risk relates to fibrosis across causes.
- •Hep B has a vaccine but no treatment; hep C has a treatment but no vaccine
- •Concerns are liver failure through steatosis, fibrosis and cirrhosis, and hepatocellular carcinoma
- •Hep B and C screening should accompany a workup for elevated transaminases
- •MASLD and alcoholic liver disease also raise cancer risk, which rises with fibrosis
- •Hep B carries about a 3-5 percent yearly cancer risk regardless of disease stage
- 15:26 – 18:47
Why ALT and AST fall short for diagnosis
Peter turns to diagnosis, noting that biopsy is the gold standard but undesirable, so noninvasive methods are used. He explains the limits of ALT and AST, using his own values and thresholds for concern.
- •Biopsy risks bleeding and infection, so noninvasive blood and imaging tests are preferred
- •ALT and AST cannot diagnose MASLD and are released when hepatocytes are stressed
- •AST is also found in muscle, so exercise can raise it; Peter's AST runs above his ALT
- •A rule of thumb is both below about 30 IU/L, and a persistent 1.5 to 2-fold rise justifies investigation
- 18:47 – 19:58
Statins and rising transaminases
The host asks whether elevated liver enzymes mean abandoning statin treatment. Peter says they would switch tools to manage cardiovascular risk, treating significant transaminase elevation as a reason to change or stop the statin.
- •Lipid-lowering drugs are a common cause of raised AST and ALT
- •Peter's practice may act at lower thresholds than guidelines suggest
- •The cardiovascular risk is still treated with other available tools
- •Significant transaminase rise, muscle symptoms and a change in insulin sensitivity are the big three reasons to move off a statin
- 19:58 – 21:36
Better tests: MR elastography, PDFF and FibroScan
Peter describes more sensitive and specific tests for quantifying liver fat and fibrosis. MR elastography with PDFF is the gold standard but costly, while FibroScan is more practical.
- •ALT and AST lack sensitivity and specificity
- •MR elastography and proton density fat fraction is the gold standard but costly and not widely available
- •Ultrasound and vibration methods are cheaper and easier in a clinic
- •FibroScan gives a CAP score, quantifying fat and fibrosis so it can serve as a biomarker to treat
- 21:36 – 24:12
Managing and improving liver health
Peter explains what to do once fat or fibrosis is confirmed. The focus is weight loss, better insulin sensitivity, and removing harmful exposures like alcohol and liquid fructose.
- •There is no clear drug indication; reducing excess adipose tissue and improving insulin sensitivity work best
- •Weight loss is simple but not easy and sometimes uses GLP-1 agonists
- •Alcohol is removed entirely in patients with steatosis or fibrosis, even if intake is modest
- •Liquid fructose and alcohol should be minimized or avoided, though fructose data are limited because study subjects lose weight
- 24:12 – 27:43
Follow-up on liver ultrasound and sneak peek wrap-up
The host asks whether Peter has all patients get a liver ultrasound or only those with other concerns. The sneak peek then ends with an explanation of premium membership benefits.
- •Question about whether ultrasound is used for all patients or only when other findings raise concern
- •The full AMA is available to premium members
- •Benefits include detailed show notes, monthly AMAs, a premium newsletter, a private feed and The Qualies
